Results 11 to 20 of about 284,282 (314)

Triple combination therapy with two antivirals and monoclonal antibodies for persistent or relapsed SARS-CoV-2 infection in immunocompromised patients.

Clinical Infectious Diseases, 2023
INTRODUCTION Severely immunocompromised patients are at risk for prolonged or relapsed COVID-19 leading to increased morbidity and mortality. We aimed to evaluate efficacy and safety of combination treatment in immunocompromised COVID-19 patients ...
M. Mikulska, Chiara Sepulcri, C. Dentone, Federica Magné, E. Balletto, F. Baldi, L. Labate, C. Russo, Michele Mirabella, L. Magnasco, C. di Grazia, Chiara Ghiggi, A. Raiola, D. Giacobbe, A. Vena, S. Beltramini, B. Bruzzone, R. Lemoli, E. Angelucci, M. Bassetti   +19 more
semanticscholar   +1 more source

2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host

Clinical Infectious Diseases, 2014
Athos Bousvaros, Lillian Sung, Marcie Tomblyn   +2 more
exaly   +2 more sources

Vaccines and therapeutics for immunocompromised patients with COVID-19

EClinicalMedicine, 2023
Summary The COVID-19 pandemic has disproportionately impacted immunocompromised patients. This diverse group is at increased risk for impaired vaccine responses, progression to severe disease, prolonged hospitalizations and deaths. At particular risk are
S. Shoham, C. Batista, Y. Ben Amor, O. Ergonul, M. Hassanain, P. Hotez, G. Kang, Jerome H. Kim, B. Lall, Heidi Larson, D. Naniche, T. Sheahan, N. Strub-Wourgaft, S. Sow, A. Wilder-Smith, P. Yadav, M. Bottazzi   +16 more
semanticscholar   +1 more source

De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report

Nature Communications, 2021
SARS-CoV-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent.
S. Gandhi, J. Klein, Alexander J Robertson, Mario A. Peña-Hernández, Michelle J. Lin, Pavitra Roychoudhury, Peiwen Lu, John B. Fournier, David Ferguson, Shah A. Mohamed Bakhash, M. Catherine Muenker, A. Srivathsan, E. Wunder, Nicholas Kerantzas, Wenshuai Wang, B. Lindenbach, A. Pyle, Craig B. Wilen, O. Ogbuagu, A. Greninger, A. Iwasaki, W. Schulz, A. Ko   +22 more
semanticscholar   +1 more source

New Insights on CMV Management in Solid Organ Transplant Patients: Prevention, Treatment, and Management of Resistant/Refractory Disease

Infectious Diseases and Therapy, 2022
Cytomegalovirus (CMV) infection can have both direct and indirect effects after solid-organ transplantation, with a significant impact on transplant outcomes.
Camille Nelson Kotton, Nassim Kamar
doaj   +1 more source

Immunocompromised Host Pneumonia: Definitions and Diagnostic Criteria: An Official American Thoracic Society Workshop Report

Annals of the American Thoracic Society, 2023
Pneumonia imposes a significant clinical burden on people with immunocompromising conditions. Millions of individuals live with compromised immunity because of cytotoxic cancer treatments, biological therapies, organ transplants, inherited and acquired ...
G. Cheng, K. Crothers, S. Aliberti, A. Bergeron, M. Boeckh, J. Chien, C. Cillóniz, K. Cohen, N. Dean, C. D. Dela Cruz, R. Dickson, A. Greninger, C. Hage, T. Hohl, S. Holland, B. Jones, J. Keane, M. Metersky, R. Miller, A. Puel, J. Ramirez, M. Restrepo, A. Sheshadri, Bashar B. Staitieh, J. Tarrand, K. Winthrop, R. Wunderink, S. Evans   +27 more
semanticscholar   +1 more source

The Burden of COVID-19 in the Immunocompromised Patient: Implications for Vaccination and Needs for the Future

Journal of Infectious Diseases, 2023
Approximately 3% of US adults are immunocompromised and less capable of fighting infections such as SARS-CoV-2 (the causative agent of COVID-19).
A. Antinori, M. Bausch-Jurken
semanticscholar   +1 more source

Remdesivir Reduced Mortality in Immunocompromised Patients Hospitalized for COVID-19 Across Variant Waves: Findings From Routine Clinical Practice

Clinical Infectious Diseases, 2023
Background Immunocompromised patients are at high risk of severe coronavirus disease 2019 (COVID-19) and death, yet treatment strategies for immunocompromised patients hospitalized for COVID-19 reflect variations in clinical practice. In this comparative
E. Mozaffari, A. Chandak, R. Gottlieb, Chidinma Chima-Melton, S. Read, Heng Jiang, Mel Chiang, EunYoung Lee, Rikisha Gupta, Mark Berry, A. Kalil   +10 more
semanticscholar   +1 more source

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

New England Journal of Medicine, 2020
SARS-CoV-2 in an Immunocompromised Host This letter describes an immunocompromised patient who had persistent infection with SARS-CoV-2 over a period of months, despite several courses of remdesivi...
Bin-Hye Choi, M. Choudhary, J. Regan, J. Sparks, R. Padera, X. Qiu, I. Solomon, H. Kuo, J. Boucau, K. Bowman, U. D. Adhikari, M. L. Winkler, Alisa A. Mueller, T. Hsu, Michaël Desjardins, L. Baden, Brian T. Chan, B. Walker, M. Lichterfeld, M. Brigl, D. Kwon, S. Kanjilal, Eugene T. Richardson, A. Jonsson, G. Alter, A. Barczak, W. Hanage, Xu G. Yu, Gaurav D. Gaiha, M. Seaman, M. Cernadas, Jonathan Z. Li   +31 more
semanticscholar   +1 more source

Mycobacterium tuberculosis Dominance over Nontuberculous Mycobacteria Irrespective of Immune Status: An Indian Scenario

Journal of Medical Microbiology and Infectious Diseases, 2022
Introduction: In HIV-associated tuberculosis cases, identifying nontuberculous Mycobacteria (NTM) from clinical samples has become essential regarding patients’ treatment and prognosis.
Soumya Dasgupta1, Oindrila Chakraborty2
doaj   +1 more source